View Older Stories View More Recent Stories

May 10, 2022 10:45AM Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
May 4, 2022 06:59AM Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference
Apr 29, 2022 06:59AM Bristol Myers Squibb Reports First Quarter Financial Results for 2022
Apr 29, 2022 06:25AM Bristol-Myers Squibb (BMY) Announces FDA Approves Camzyos for Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive HCM
Apr 28, 2022 08:01PM U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to
Apr 21, 2022 06:59AM Bristol-Myers Squibb (BMY) and EDP Renewables Announces 15-Year Power Purchase Agreement for the Cattlemen Solar Park
Apr 21, 2022 06:59AM EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
Apr 18, 2022 09:23AM Pre-Open Stock Movers 04/18: Casa Systems and Natus Medical Higher; TG Therapeutics and Nektar Lower (more...)
Apr 14, 2022 04:33PM Nektar Therapeutics (NKTR) and Bristol Myers Squibb (BMY) End Bempegaldesleukin in Combination with Opdivo Program
Apr 14, 2022 04:30PM Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
Apr 11, 2022 11:17AM Bristol-Myers Squibb (BMY) Announces Neoadjuvant Opdivo with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable NSCLC in Phase 3 CheckMate -816 Trial
Apr 11, 2022 11:15AM Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Apr 5, 2022 10:35AM Bristol-Myers Squibb (BMY) Receives EU Approval for Breyanzi for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
Apr 5, 2022 10:33AM Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
Apr 5, 2022 06:55AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
Apr 5, 2022 06:51AM Bristol-Myers Squibb (BMY) Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with ESCC
Apr 5, 2022 06:50AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
Apr 5, 2022 06:45AM Bristol-Myers Squibb (BMY) Granted EU Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression �
Apr 5, 2022 06:45AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor
Apr 3, 2022 09:45AM Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive
Apr 2, 2022 09:30AM Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial
Mar 29, 2022 06:59AM Bristol-Myers Squibb (BMY) Announces EMA Validates its Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
Mar 29, 2022 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
Mar 25, 2022 06:59AM Bristol-Myers Squibb (BMY) Announces June 27, 2022 as New Prescription Drug User Fee Act Goal Date for Reblozyl
Mar 25, 2022 06:59AM Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application
Mar 21, 2022 08:00AM Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
Mar 21, 2022 05:54AM Bristol-Myers Squibb (BMY) Announces FDA Approval of Opdualag as Treatment for Patients with Unresectable or Metastatic Melanoma
Mar 18, 2022 06:29PM U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma
Mar 14, 2022 07:00AM Bristol-Myers Squibb (BMY), Nektar (NKTR) Announce Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo Did Not Meet Primary Endpoint
Mar 14, 2022 06:59AM Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metas
Mar 11, 2022 06:59AM Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022
Mar 9, 2022 06:59AM Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16
Mar 4, 2022 05:50PM Bristol-Myers Squibb (BMY) Announces FDA Approval of Opdivo with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
Mar 4, 2022 05:44PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
Mar 2, 2022 03:19PM Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Mar 1, 2022 09:03PM Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers
Mar 1, 2022 04:16PM Bristol Myers Squibb Announces Dividend
Mar 1, 2022 01:00PM Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
Feb 28, 2022 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review Application for Opdivo Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
Feb 28, 2022 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung
Feb 25, 2022 06:57AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell
Feb 25, 2022 06:55AM Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamou
Feb 25, 2022 06:50AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or
Feb 25, 2022 06:45AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma wi
Feb 25, 2022 06:45AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcin
Feb 17, 2022 12:19PM Bristol-Myers Squibb (BMY) Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active UC
Feb 17, 2022 12:19PM Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerativ
Feb 17, 2022 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review BLA for Breyanzi as Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
Feb 17, 2022 06:59AM U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy
Feb 16, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports Positive Topline Results from Phase 3 VALOR-HCM Trial
View More Recent Stories View Older Stories